ETRM Key Stats
- Trend Report: 7 Insider And Hedge Fund Stock Picks To Consider The Street 02/28 12:35 ET
- EnteroMedics to Present at the Cowen and Company 34th Annual Health Care Conference noodls 02/25 09:02 ET
- 7:01 am EnteroMedics announces FDA Advisory Committee meeting date for review of the Maestro Rechargeable System for the treatment of obesity; Center for Devices and Radiologic Health Advisory Committee scheduled for May 29, 2014 Yahoo 02/12 18:58 ET
- ENTEROMEDICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financial Statement Yahoo 02/12 10:45 ET
- EnteroMedics Announces Food and Drug Administration Advisory Committee Meeting Date for Review of the Maestro(R) Rechargeable System for the Treatment of Obesity noodls 02/12 10:28 ET
- EnteroMedics Reports Fourth Quarter 2013 Financial Results noodls 02/12 10:28 ET
- EnteroMedics announces FDA Advisory Committee metting date for Maestro System Yahoo 02/12 07:18 ET
- EnteroMedics, Inc. (ETRM) Reports Q4 Loss of $0.11 Street Insider 02/12 07:10 ET
- EnteroMedics (ETRM) PT Raised to $6 at Craig-Hallum Street Insider 01/06 09:11 ET
- Profit From The War On Obesity With This Left-For-Dead Stock 01/03 08:00 ET
ETRM Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). EnteroMedics is up 154.6% over the last year vs S&P 500 Total Return up 24.21%, Cardiovascular Systems up 113.8%, and NuVasive up 88.38%.
Balance Sheet View Statement
Pro Ratings for ETRM
Pro Strategies Featuring ETRM
Did EnteroMedics make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
- Sector: Healthcare
- Industry: Medical Devices
- Headquarters Country: United States
- Headquarters State/Province: Minnesota
- Incorporation Country: United States
- Incorporation State/Province: Delaware
EnteroMedics, Inc., a development stage medical device company engaged in design and development of devices that use neuroblocking technology to treat obesity, its associated co-morbidities, and other gastrointestinal disorders.